undamentalytics Newsletter
Sign in

GSK plc (GSK) stock

Add to watchlist

Add holding +

NYSE: GSK NYSE Pharmaceuticals

B Fundamentals grade

GSK plc is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$58

Cash-flow model

Base case. Range ~$41–$80 across our lower- and higher-growth cases (1.7%–11.7% a year).

Price vs value

Modestly undervalued

The price is inside our value range, 16% below our base value.

Price used: $48.67, November 3, 2026

GSK plc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds464 adding, 416 cuttingOf 57 active managers that changed their stake, 31 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter GSK files

Where GSK stands after its latest Filing

Revenue for the twelve months was $43.1bn, up 7.5% on a year earlier, faster than the 6.3% growth a quarter earlier. Free-cash-flow margin fell to 19.6% from 28.4% a year earlier. Operating margin widened to 24.3% from 17.6%. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 3 of our 7 financial-health checks. Our cash-flow model value is $58.14 a share, against a share price of $49.51. At that price, our model says the market is pricing in about 4.3% a year of cash-flow growth for five years, slower than the 6.6% a year revenue growth it has delivered.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

GSK plc's trailing-twelve-month revenue grew 7.5% year on year, with a free-cash-flow margin of 19.6%. Where it stands out: operating margin of 24.3% ranks 8 of 67 pharmaceuticals companies we cover.

Our discounted-cash-flow model values the business at ~$58 per share in the base case (~$41–$80 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 28.0% while net income grew 129.1%: a 101pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 11.5 points on a year ago.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Weakest spot: days sales outstanding. Days sales outstanding of 85 days ranks 37 of 59 pharmaceuticals companies we cover (median 72 days).

Latest results

Earnings per share
$1.45 against an average estimate of $1.33: beat by 9.5%
Next report
October 28, 2026

GSK's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.9%
  • 1 week-4.5%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$43.1B
Operating margin
24.3%
Net margin
17.5%
EPS (TTM, diluted)
$3.66

Growth

Revenue growth
+7.5%
Change in growth rate
+1.2 pts
Share count change
−0.6%

Cash

Free cash flow (TTM)
$8.4B
FCF margin
19.6%
Stock pay % of revenue
1.1%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for GSK from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

GSK plc valuation models and calculator

What the price is pricing in

The share price implies about 4.0% a year of cash-flow growth for five years.That is close to the 6.6% a year revenue growth GSK has delivered.

  • Priced in4.0%
  • Last 12 months7.5%
  • 3 years a year5.9%
  • 5 years a year6.6%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($48.63, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$58
Price used
$48.63close November 3, 2026
Implied change
▲ +20%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of GSK plc's free cash flow after stock-based pay with after-tax interest added back ($6.4B, FY2025 Q4 TTM), growing 6.7% a year for five years and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$41–~$80 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of GSK plc's free cash flow after stock-based pay ( $6.4B, FY2025 Q4 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value GSK plc as an operating company, with every model that fits that kind of business. Cost of equity 8.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.86 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$58 ~$41–$80 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$49 ~$44–$100 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: return on equity above 40%: buybacks or intangibles make book value too small an anchor
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$65 ~$55–$78 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$58 ~$49–$65 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare GSK plc with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −28%
  • Revenue growth 5 points higher ▲ +36%
  • Free-cash-flow margin 1 point lower ▼ −6%
  • Last year's free-cash-flow margin change, if it persists ▲ +22%
  • Discount rate 1 point higher ▼ −17%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $36$52$73$101$137$185
8.5% $25$37$52$72$98$132
10% $19$28$39$55$75$100

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for GSK plc: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $1.33 $1.45 +9.5%
Jun 2026 $1.25 $1.34 +7.2%
Mar 2026 $1.16 $1.26 +7.9%
Dec 2025 $0.62 $0.70 +11.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

9 analysts, Nov 2026
Buy333%
Hold556%
Sell111%

Monthly trend

  1. Nov 202612519
  2. Oct 202612418
  3. Sep 202611518

Counts of recommendations published by analysts covering GSK plc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.7%
of tradable shares
Days to cover
2.86
at average volume
Short interest, 1 month
−0%
to October 15, 2026
Held by institutions
17%
of shares
Held by insiders
0.1%
of shares
Employees
66,841
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Options strategies

All options ideas

How GSK plc’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 3, 2026. Check the live chain at your broker before trading.

Implied vs realised volatility

Not enough history

There is not enough price history to measure realised volatility.

  • Puts and calls are priced at about the same implied volatility.
  • Why: not enough price history to measure realised volatility.

Our rule for “rich”: implied at least 1.2× 60-day realised (beyond measurement noise), above 1-year realised (not just a calm spell), and in the top 20% of our coverage that day. Never with results inside the option’s life. These are our conventions, built on research showing option prices usually imply more movement than follows, most when the gap is wide. How we judge this.

Cash-secured put

Not offered: fundamentals grade B (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

GSK plc in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) GSK plc
$30B $35B $40B $45B FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY15 Q4: $36.6B Revenue (TTM), FY16 Q4: $37.8B Revenue (TTM), FY17 Q4: $38.9B Revenue (TTM), FY18 Q4: $41.2B Revenue (TTM), FY19 Q4: $43.1B Revenue (TTM), FY20 Q4: $31.2B Revenue (TTM), FY21 Q4: $34B Revenue (TTM), FY22 Q4: $36.3B Revenue (TTM), FY23 Q4: $37.7B Revenue (TTM), FY24 Q4: $40.1B Revenue (TTM), FY25 Q4: $43.1B $43.1B

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY15 Q4 $36.6B
FY16 Q4 $37.8B
FY17 Q4 $38.9B
FY18 Q4 $41.2B
FY19 Q4 $43.1B
FY20 Q4 $31.2B
FY21 Q4 $34B
FY22 Q4 $36.3B
FY23 Q4 $37.7B
FY24 Q4 $40.1B
FY25 Q4 $43.1B
Revenue growth, TTM YoY GSK plc
-30% -20% -10% 0% 10% FY16 Q4 FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue growth, TTM YoY, FY16 Q4: 3.4% Revenue growth, TTM YoY, FY17 Q4: 2.9% Revenue growth, TTM YoY, FY18 Q4: 5.8% Revenue growth, TTM YoY, FY19 Q4: 4.6% Revenue growth, TTM YoY, FY20 Q4: -27.5% Revenue growth, TTM YoY, FY21 Q4: 8.8% Revenue growth, TTM YoY, FY22 Q4: 6.7% Revenue growth, TTM YoY, FY23 Q4: 4.0% Revenue growth, TTM YoY, FY24 Q4: 6.3% Revenue growth, TTM YoY, FY25 Q4: 7.5% 7.5%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY16 Q4 3.4%
FY17 Q4 2.9%
FY18 Q4 5.8%
FY19 Q4 4.6%
FY20 Q4 -27.5%
FY21 Q4 8.8%
FY22 Q4 6.7%
FY23 Q4 4.0%
FY24 Q4 6.3%
FY25 Q4 7.5%
Operating margin (TTM) GSK plc
0% 20% 40% 60% FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Operating margin (TTM), FY15 Q4: 43.1% Operating margin (TTM), FY16 Q4: 9.3% Operating margin (TTM), FY17 Q4: 13.5% Operating margin (TTM), FY18 Q4: 17.8% Operating margin (TTM), FY19 Q4: 20.6% Operating margin (TTM), FY20 Q4: 24.6% Operating margin (TTM), FY21 Q4: 17.6% Operating margin (TTM), FY22 Q4: 21.9% Operating margin (TTM), FY23 Q4: 22.2% Operating margin (TTM), FY24 Q4: 12.8% Operating margin (TTM), FY25 Q4: 24.3% 24.3%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY15 Q4 43.1%
FY16 Q4 9.3%
FY17 Q4 13.5%
FY18 Q4 17.8%
FY19 Q4 20.6%
FY20 Q4 24.6%
FY21 Q4 17.6%
FY22 Q4 21.9%
FY23 Q4 22.2%
FY24 Q4 12.8%
FY25 Q4 24.3%
FCF margin (TTM) GSK plc
0% 10% 20% 30% 40% FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 FCF margin (TTM), FY15 Q4: 5.0% FCF margin (TTM), FY16 Q4: 17.8% FCF margin (TTM), FY17 Q4: 17.8% FCF margin (TTM), FY18 Q4: 23.0% FCF margin (TTM), FY19 Q4: 20.0% FCF margin (TTM), FY20 Q4: 30.6% FCF margin (TTM), FY21 Q4: 28.4% FCF margin (TTM), FY22 Q4: 21.3% FCF margin (TTM), FY23 Q4: 18.0% FCF margin (TTM), FY24 Q4: 16.4% FCF margin (TTM), FY25 Q4: 19.6% 19.6%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY15 Q4 5.0%
FY16 Q4 17.8%
FY17 Q4 17.8%
FY18 Q4 23.0%
FY19 Q4 20.0%
FY20 Q4 30.6%
FY21 Q4 28.4%
FY22 Q4 21.3%
FY23 Q4 18.0%
FY24 Q4 16.4%
FY25 Q4 19.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F, 20-F/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar GSK took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $43.1B
  2. Cost of revenue $11.9B · 27.6%
  3. Gross profit $31.2B · 72.4%
  4. Research and development $9.9B · 23.0%
  5. Selling, general and admin $266M · 0.6%
  6. Other operating costs $10.5B · 24.5%
  7. Operating income $10.5B · 24.3%
  8. Income tax $1.5B · 3.4%
  9. Interest and other $1.5B · 3.4%
  10. Net income $7.5B · 17.5%

Shares of revenue. Source: GSK's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 36.6 37.8 38.9 41.2 43.1 31.2 34.0 36.3 37.7 40.1 43.1
Gross profit 23.0 25.2 25.6 27.5 28.0 21.1 22.8 24.5 27.1 28.5 31.2
EBITDA 18.3 5.9 7.7 9.8 11.9 10.3 8.9 10.6 11.2 8.4 13.5
Operating income 15.8 3.5 5.3 7.3 8.9 7.7 6.0 8.0 8.4 5.1 10.5
Net income 12.9 1.2 2.0 4.8 5.9 7.4 6.0 18.5 6.1 3.3 7.5
Diluted EPS $6.58 $0.63 $1.00 $2.44 $2.96 $3.66 $2.98 $9.06 $2.98 $1.59 $3.66
Growth (year on year)
Revenue — +3.4% +2.9% +5.8% +4.6% −27.5% +8.8% +6.7% +4.0% +6.3% +7.5%
EBITDA — −67.6% +30.7% +26.6% +21.0% −13.2% −13.4% +19.0% +5.9% −25.3% +60.9%
Operating income — −77.7% +49.6% +39.1% +21.3% −13.7% −21.8% +32.7% +5.4% −38.7% +103.6%
Net income — −90.4% +59.7% +145.2% +22.5% +24.4% −18.2% +206.6% −66.9% −46.3% +129.1%
Diluted EPS — −90.4% +58.5% +143.8% +21.4% +23.8% −18.6% +204.2% −67.1% −46.7% +130.3%
Margins
Gross margin 63.0% 66.7% 65.7% 66.8% 64.9% 67.4% 66.9% 67.4% 71.8% 71.2% 72.4%
EBITDA margin 50.0% 15.7% 19.9% 23.8% 27.5% 33.0% 26.2% 29.3% 29.8% 20.9% 31.4%
Operating margin 43.1% 9.3% 13.5% 17.8% 20.6% 24.6% 17.6% 21.9% 22.2% 12.8% 24.3%
Net margin 35.2% 3.3% 5.1% 11.8% 13.8% 23.6% 17.8% 51.0% 16.2% 8.2% 17.5%
Free-cash-flow margin 5.0% 17.8% 17.8% 23.0% 20.0% 30.6% 28.4% 21.3% 18.0% 16.4% 19.6%
Cash flow
Cash from operations 3.9 8.8 8.9 11.3 10.2 10.8 10.9 9.2 8.4 8.4 10.2
Capital spending 2.1 2.1 2.0 1.8 1.6 1.3 1.3 1.4 1.6 1.8 1.8
Free cash flow 1.8 6.7 6.9 9.5 8.6 9.6 9.6 7.7 6.8 6.6 8.4
Stock-based pay 0.6 0.4 0.4 0.5 0.5 0.4 0.5 0.4 0.4 0.4 0.5
Free cash flow after stock pay 1.3 6.3 6.5 9.0 8.2 9.1 9.2 7.3 6.4 6.1 7.9
Balance sheet
Cash 8.6 6.0 5.2 4.9 6.2 8.6 5.8 4.5 3.7 4.8 4.6
Total debt 15.8 23.2 23.1 33.3 40.5 37.1 32.6 25.3 23.0 21.3 23.8
Net debt (negative = net cash) 7.2 17.1 17.9 28.3 34.2 28.5 26.9 20.8 19.2 16.4 19.3
Diluted shares 1,955m 1,964m 1,976m 1,988m 2,006m 2,015m 2,026m 2,042m 2,056m 2,071m 2,059m
Returned to shareholders
Dividends — — −5.0 — — — — — — — —
Buybacks — — — — — — — — 0.0 0.0 1.8
Total returned — — −5.0 — — — — — 0.0 0.0 1.8

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 7 checks passed · December 31, 2025
What it owns · $82.2bn
Short-term assets $23.5bnLonger-term assets $58.6bn
What it owes, and who funded it · $82.8bn
Short-term liabilities $28.8bnLonger-term liabilities $32.0bnShareholders' equity $22.0bn
  • Short-term assets cover short-term liabilities $23.5bn of assets due within a year against $28.8bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $23.5bn short-term assets against $32.0bn of longer-dated liabilities.
  • More cash than debt $4.6bn of cash against $23.8bn of debt.
  • Debt below 40% of shareholders' equity Debt is 108% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 161% to 108% over five years.
  • A year's operating cash flow covers at least 20% of debt $10.2bn of operating cash flow against $23.8bn of debt.
  • Operating profit covers interest at least five times over Operating income of $10.5bn against $61m of interest.

From GSK plc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$1.8B
Buybacks, last 3 fiscal years
$1.8B
Diluted share count
−0.6%
year over year
Total shareholder yield
1.8%
dividends 0.0% + buybacks 1.8% of market value
R&D spending
23.0%
of revenue
Days sales outstanding
85 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated GSK NVO BMY AZN PFE MRK Median
Revenue, last 12 months $43.1bn $46.8bn $50.0bn $58.7bn $63.7bn $66.6bn $276m
Revenue growth, last 12 months 7.5% 11.1% 4.2% 8.6% −0.2% 4.6% 9.9%
Revenue growth, 3-year average — — 3.6% — −7.0% 4.5% 5.5%
Revenue growth, latest quarter — — 6.9% — 2.6% 5.1% 6.5%
Gross margin 72.4% 81.0% 69.2% 81.9% 73.2% 73.0% 62.0%
Operating margin 24.3% 41.3% — 23.4% — — −5.9%
Operating margin, 3-year average 18.5% — — 14.2% — — −7.4%
Net margin 17.5% 33.1% 18.5% 17.4% 6.8% 4.8% −7.3%
Cash from operations / revenue 23.7% 38.5% 21.3% 24.8% 21.0% 30.0% 10.2%
Free-cash-flow margin 19.6% 19.1% 18.6% 20.0% 17.2% 24.1% 8.6%
Free-cash-flow margin, 3-year average 21.9% — 26.5% 14.4% 15.1% 22.8% 7.4%
Stock pay / revenue 1.1% 0.5% 1.1% 1.2% 1.5% 1.3% 3.6%
Change in share count −0.6% −0.3% 0.6% −0.1% 0.2% −1.9% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 7.5% 10.0% 43 of 74
Change in growth rate Growth +1.2pp -0.3pp 30 of 74
Gross margin Profitability 72.4% 59.8% 16 of 59
Operating margin Profitability 24.3% -5.9% 8 of 67
Net margin Profitability 17.5% -7.3% 13 of 75
Free-cash-flow margin Cash generation 19.6% 10.1% 22 of 74
Stock pay as % of revenue Cash generation 1.1% 3.6% 14 of 69
Long-term debt as % of assets Balance sheet 24.1% 23.8% 28 of 53
Change in share count Balance sheet -0.6% 1.5% 16 of 62
Days sales outstanding Balance sheet 85 days 72 days 37 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$18.2B
Institutions reporting
1,029
Shares held vs prior quarter
▼ 7.4%
Positions opened / closed
90 / 80

Top buyers and sellers, Q2 2026: 464 institutions bought and 416 sold ; the biggest buyer was Point72 Asset Management, L.P (+2.7M shares) and the biggest seller Dodge & Cox (−10.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $3.4B 65.0M 18.8% ▼ 4.0%
Dodge & Cox $2.5B 48.2M 13.9% ▼ 17.8%
Fisher Asset Management, LLC $1.9B 35.7M 10.3% ▲ 3.5%
Primecap Management Co $1.3B 25.2M 7.3% ▼ 0.1%
Wellington Management Group LLP $597M 11.4M 3.3% ▼ 2.7%
Jtc Employer Solutions Trustee Ltd $450M 8.6M 2.5% ▼ 5.0%
Morgan Stanley $401M 7.7M 2.2% ▼ 30.6%
Royal Bank Of Canada $398M 7.6M 2.2% ▲ 1.1%
Price T Rowe Associates Inc $363M 6.9M 2.0% ▼ 5.5%
Acadian Asset Management LLC $349M 6.7M 1.9% ▼ 43.5%
Goldman Sachs Group Inc $334M 6.4M 1.8% ▼ 33.6%
State Street Corp $315M 6.0M 1.7% ▼ 0.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not GSK plc's complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 74 trades and filings

No trades in GSK plc disclosed in the last 12 months; 74 earlier trades on record.

  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded October 31, 2025, filed November 21, 2025
  • Lisa C. McClain(R-MI 9):Purchase, $1,001 - $15,000, traded October 30, 2025, filed November 21, 2025
  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded October 30, 2025, filed November 21, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Data status

When each part of this page on GSK plc was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

GSK plc in brief

What does GSK plc do?
GSK plc is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is GSK plc's stock ticker?
GSK plc trades under the ticker GSK on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is GSK plc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, GSK plc reported revenue of $43.1B, 7.5% higher than a year earlier, according to its SEC filings.
What is GSK plc's free cash flow?
GSK plc's free-cash-flow margin is 19.6% of revenue over the trailing twelve months, ranking 22 of the 74 pharmaceuticals companies we cover.
What is GSK plc's fair value (intrinsic value) per share?
Our discounted-cash-flow model of GSK plc's free cash flow after stock-based pay gives ~$58 per share in the base case, and ~$41–$80 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are GSK plc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Dodge & Cox and Fisher Asset Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is GSK plc buying back stock, and does it pay a dividend?
GSK plc spent $1.8B on share repurchases over the trailing twelve months, and its diluted share count fell 0.6% over the year.
How much debt does GSK plc have?
GSK plc's debt-to-equity ratio is 108.2%, from its latest balance sheet (160.6% five years earlier). The financial health section below sets out its other solvency checks.
Who are GSK plc's competitors?
In our Pharmaceuticals peer group, the companies closest to GSK plc are Novo Nordisk A S, Bristol Myers Squibb, Astrazeneca PLC, Pfizer and Merck & Co. The side-by-side comparison below sets their revenue, margins and growth against GSK plc's.